Abstract 1745: Translational medicine enables rapid early clinical development of AVL-292, a highly selective, orally available inhibitor of Bruton's tyrosine kinase, in a phase 1b clinical trial

Phase 1B ◽

Early Clinical Development

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development

Journal of Medicinal Chemistry ◽

10.1021/acs.jmedchem.7b01712 ◽

2018 ◽

Vol 61 (6) ◽

pp. 2227-2245 ◽

Cited By ~ 67

Author(s):

James J. Crawford ◽

Adam R. Johnson ◽

Dinah L. Misner ◽

Lisa D. Belmont ◽

Georgette Castanedo ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Clinical Development ◽

Early Clinical Development

Preclinical Mechanism of Action of PRN1008, a Reversible Covalent Bruton’s Tyrosine Kinase Inhibitor in Clinical Development for Pemphigus

10.26226/morressier.5d4980c98fb7e44098e72b12 ◽

2019 ◽

Author(s):

Claire Langrish ◽

Kristin MacIntosh

Keyword(s):

Tyrosine Kinase ◽

Mechanism Of Action ◽

Kinase Inhibitor ◽

Clinical Development ◽

Reversible Covalent

011 Preclinical Mechanism of Action of PRN1008, a Reversible Covalent Bruton’s Tyrosine Kinase Inhibitor in Clinical Development for Pemphigus

Journal of Investigative Dermatology ◽

10.1016/j.jid.2019.07.014 ◽

2019 ◽

Vol 139 (9) ◽

pp. S216

Author(s):

C.L. Langrish ◽

M.R. Francesco ◽

Y. Xing ◽

J.M. Bradshaw ◽

T.D. Owens ◽

...

Keyword(s):

Tyrosine Kinase ◽

Mechanism Of Action ◽

Kinase Inhibitor ◽

Clinical Development ◽

Reversible Covalent

PS1148 PRELIMINARY RESULTS OF A PHASE 1B/2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF THE NONCOVALENT, REVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), VECABRUTINIB, IN B-CELL MALIGNANCIES

HemaSphere ◽

10.1097/01.hs9.0000562876.57990.65 ◽

2019 ◽

Vol 3 (S1) ◽

pp. 520 ◽

Cited By ~ 3

Author(s):

J.N. Allan ◽

K. Patel ◽

A.R. Mato ◽

W.G. Wierda ◽

J. Pinilla-Ibarz ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Dose Escalation ◽

Kinase Inhibitor ◽

B Cell Malignancies ◽

Preliminary Results ◽

Phase 1B

Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

Haematologica ◽

10.3324/haematol.2021.280061 ◽

2021 ◽

Author(s):

John N. Allan ◽

Javier Pinilla-Ibarz ◽

Douglas E. Gladstone ◽

Krish Patel ◽

Jeff P. Sharman ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Dose Escalation ◽

Kinase Inhibitor ◽

B Cell Malignancies ◽

Dose Escalation Study ◽

Phase 1B

Not available.

A phase 1b trial of duvelisib, a PI3K-δ,γ inhibitor, in combination with obinutuzumab in patients with CLL/SLL previously treated with a Bruton’s tyrosine kinase inhibitor (BTKi).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps7100 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS7100-TPS7100 ◽

Cited By ~ 1

Author(s):

James Stewart Blachly ◽

Jennifer R. Brown ◽

Jacqueline Claudia Barrientos ◽

Nitin Jain ◽

Virginia Kelly ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Previously Treated ◽

Phase 1B

Bruton's tyrosine kinase regulates human INTERLEUKIN-10 (IL-10) producing B regulatory cell (Bregs) induction and function

10.26226/morressier.594a7d44d462b8028d8931d6 ◽

2017 ◽

Author(s):

Vassilios Lougaris

Keyword(s):

Tyrosine Kinase ◽

Interleukin 10 ◽

Regulatory Cell ◽

And Function

Faculty Opinions recommendation of Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1001957.11564 ◽

2001 ◽

Author(s):

Andy Chan

Keyword(s):

Tyrosine Kinase ◽

Binding Protein ◽

Direct Inhibition ◽

Bruton's Tyrosine Kinase

Faculty Opinions recommendation of Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1064714.518656 ◽

2007 ◽

Author(s):

Steve Ward

Keyword(s):

Cell Migration ◽

Tyrosine Kinase ◽

B Cell ◽

Bruton's Tyrosine Kinase

Faculty Opinions recommendation of Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733329282.793547860 ◽

2018 ◽

Author(s):

Thomas Kodadek

Keyword(s):

Tyrosine Kinase ◽

Resistance Mutation ◽

Ibrutinib Resistance